Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection
- Registration Number
- NCT02694848
- Lead Sponsor
- China Academy of Chinese Medical Sciences
- Brief Summary
To evaluate the therapeutic evaluation of combination therapy with aspirin and salvianolate injection based on the population pharmacokinetics and TEG.A prospective, multicenter, randomized, controlled clinical trial is used.A total of 120 patients will be recruited and will be divided into three groups,respectively salvianolate injection group,aspirin group and salvianolate injection and aspirin group，and the course of treatment is 10 days.
- Detailed Description
1. Effectiveness evaluation:Primary Outcome Measure:Change of TEG（R time, K time, α angle, MA,CI,TPI）.Secondary Outcome Measures: Change of symptom score of the Seattle Angina Questionnaiire(SAQ).Change of ECG abnormalities.Change of score of traditional Chinese medicine(TCM) symptom curative effect rating scale. Change of platelet aggregation measured by light transmittance aggregometry(LTA).Change of serum lipids（TC、TG、HDL-C、LDL-C）.Change of fasting blood glucose.Population pharmacokinetics test(the detection of the blood concentration of magnesium lithospermate B and salicylic acid).
2. Safety evaluation:Change of PT,APTT,TT,FIB.Adverse events.Change of basic life sign.Gastrointestinal symptoms.Change of stool routine.Change of routine blood test.Change of urine routine.Change of liver function.Change of renal function.Change of fecal occult blood.
3. Number of participants:120 participants will be divided into three groups, the salvianolate group (n=40), the aspirin group(n=40) and the combination therapy group of salvianolate injection and aspirin(n=40).
4. Interventions:salvianolate injection group: salvianolate injection, intravenously infusion,0.2g/time, once a day; other routine treatment according to the condition of the disease.Aspirin group: aspirin, oral administration method,0.1g/time, once a day; other routine treatment according to the condition of the disease.Salvianolate injection and aspirin group: salvianolate injection, intravenously infusion,0.2g/time, once a day; aspirin, oral administration method,0.1g/time, once a day; other routine treatment according to the condition of the disease.
5. Course of treatment：10 days.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 120
- Patient age 35-75 years old
- Grade II diagnostic criteria for chronic stable angina pectoris
- Diagnostic criteria of blood stasis type
- Signed informed consent
- Drug allergy to the test
- There is a family or personal history of hemorrhagic disease
- Platelet count < 100 * nine times square 10/L or > 450 *nine times square 10/L
- Hemoglobin < 90g/L
- ALT, AST higher than the upper limit of 2 times, BUN, Cr higher than the upper limit
- Drugs such as the use of clopidogrel, clopidogrel, Hua Falin or heparin in the last 2 weeks to take blood circulation drugs or other antiplatelet, anticoagulant or non steroidal anti-inflammatory drugs
- Heart failure three degrees, two degrees in patients with heart failure
- A history of trauma or surgery in the past 2 weeks
- Combined coronary heart disease myocardial infarction and cerebral blood vessels, liver, kidney, hematopoietic system severe primary disease, malignant tumor, mental disease patients, as well as hyperthyroidism, cervical spondylosis, stomach and esophageal reflux and other patients with chest pain
- Organ transplantation, AIDS, long-term use of immunosuppressive agents and other immune deficiency
- Pregnant or lactating women
- Other clinical trial participants who are taking part in the evaluation of the results of this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Salvianolate injection group Salvianolate injection Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease Salvianolate injection and aspirin group Salvianolate injection Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease Aspirin group Aspirin Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease Salvianolate injection and aspirin group Aspirin Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
- Primary Outcome Measures
Name Time Method Change of thromboela-stogram（R time,K time,α angle,MA、CI、TPI） Change from base line on the tenth day Thromboela-stogram(TEG) Is a reflection of the dynamic changes in blood coagulation (including the formation rate of fibrin, the dissolution of the state and the consistency of the solid, elastic degree) of the index: R time is the latency of the first fibrin plaque formation. K time is to assess the rate at which blood clots reach a certain level. The alpha angle is similar to the K time, but is more comprehensive than the K time, and is not affected by the low coagulation state. MA reflects the maximum amplitude of blood clots. CI is an integrated coagulation index.TPI is the index of platelet kinetics
- Secondary Outcome Measures
Name Time Method Change of symptom score of the Seattle Angina Questionnaiire(SAQ) Change from base line on the tenth day SAQ includes 5 dimensions: the degree of physical activity limitation, the stable state of angina pectoris, the frequency of angina attack, the degree of treatment satisfaction, and the recognition of the disease
Change of ECG abnormalities Change from base line on the tenth day ECG is the most common method of detection of myocardial ischemia and the diagnosis of angina pectoris
Change of score of Traditional Chinese Medicine(TCM) symptom curative effect rating scale Change from base line on the tenth day It includes the description of scores of symptoms, signs of tongue and pulse related to blood stasis syndrome of diagnosis of traditional Chinese medicine
Change of platelet aggregation measured by light transmittance aggregometry(LTA) Change from base line on the tenth day The method is widely recognized, and is even considered a gold standard
Change of serum lipids（TC、TG、HDL-C、LDL-C） Change from base line on the tenth day Hyperlipidemia is one of the causes of angina. The measurement units of four indicators（TC、TG、HDL-C、LDL-C）are "mmol/L"
Change of fasting blood glucose Change from base line on the tenth day It is one of the causes of angina(especially for patients with diabetes).The measurement unit is "mmol/L"
The blood concentration of magnesium lithospermate B At the discretional two time points from the time point after treatment(0h,0.25h(15min),0.5h,0.75h(45min),1h,1.17h(70min),1.33h(80min),1.67h(100min),2h,2.5h,3h,4h,5h,7h,9h,13h,25h) Population pharmacokinetics test is in order to study the relationship between the population pharmacokinetics and clinical outcome. Magnesium lithospermate B is the main effective components of Salvianolate injection.The detection of the blood concentration of magnesium lithospermate B from both salvianolate injection group and salvianolate injection and aspirin group is necessary.
The blood concentration of salicylic acid At the discretional two time points from the time point after treatment(0h,0.5h,1h,1.5h,2h,2.5h,3h,4h,5h,6h,8h,9h,10h,12h) Population pharmacokinetics test is in order to study the relationship between the population pharmacokinetics and clinical outcome. Salicylic acid is a kind of metabolite of aspirin. The detection of the blood concentration of salicylic acid from both aspirin group and salvianolate injection and aspirin group is necessary.
Trial Locations
- Locations (1)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
🇨🇳Beijing, Beijing, China